The special dividend is a deal-contingent capital return, not an operating signal. The key catalyst remains the November 2, 2026 merger vote and closing. Monitor stockholder approvals and any regulatory conditions that could delay or break the deal — if the merger fails, the dividend is not paid.
Price Chart
Executive Summary
Indivior declared an $8.13 per share special cash dividend contingent on closing its pending merger with Supernus Pharmaceuticals. The dividend is a return-of-capital distribution funded by incremental debt, payable only if the merger closes (expected ~Nov 2, 2026). This is a routine procedural step in the merger process — the dividend itself is not a standalone operating event.
Key Facts
- Board declared a special cash dividend of $8.13 per share on September 16, 2026.
- Dividend is payable to holders of record as of October 30, 2026, and to holders of certain equity awards.
- Payment is contingent upon closing of the merger with Supernus Pharmaceuticals, expected on or about November 2, 2026.
- At least a majority of the special dividend is expected to exceed Indivior's current and accumulated earnings and profits, treated as a return of capital for U.S. holders.
- Supernus stockholders will not receive the special dividend on Indivior common stock received as merger consideration.
- The 8-K is also filed as a Rule 425 written communication under Rule 425 in connection with the merger.
Financial Impact
$8.13 per share special cash dividend per share, contingent on merger close. No aggregate dollar amount or total dollar amount provided.
Risk Factors
- Dividend is not paid if merger fails to close for any reason.
- Additional indebtedness incurred to fund the special dividend could increase leverage at the combined company.
- At least a majority of the dividend exceeding earnings and profits creates a return-of-capital tax treatment, which may affect holder tax positions.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-108417 |
| Document: tm2623753d7_ex99-1.htm | 0001104659-26-108417 |
| Document: 0001104659-26-108417-index-headers.html | 0001104659-26-108417 |
| Document: 0001104659-26-108417-index.html | 0001104659-26-108417 |
| Document: 0001104659-26-108417.txt | 0001104659-26-108417 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | Institutional Cluster | $34.79 | awaiting T+60 | — | $34.43 (−1.03%) |
Oct 19, 2026 8d ago | Press Release | $33.87 | awaiting T+60 | — | $34.43 (+1.65%) |
Oct 6, 2026 21d ago | 425 | $35.90 | awaiting T+60 | — | $34.43 (−4.09%) |
Oct 6, 2026 21d ago | 8-K | $35.90 | awaiting T+60 | — | $34.43 (−4.09%) |
Sep 30, 2026 26d ago | SC 13G | $35.38 | awaiting T+60 | — | $34.43 (−2.69%) |
Sep 17, 2026 5w ago | 425 | $35.69 | awaiting T+60 | — | $34.43 (−3.53%) |
Sep 17, 2026 5w ago | 8-K | $35.69 | awaiting T+60 | — | $34.43 (−3.53%) |
Sep 17, 2026 5w ago | Press Release | $35.69 | awaiting T+60 | — | $34.43 (−3.53%) |
Sep 14, 2026 6w ago | EFFECT | $34.47 | awaiting T+60 | — | $34.43 (−0.12%) |
Aug 28, 2026 8w ago | S-4 | $34.93 | awaiting T+60 | — | $34.43 (−1.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers